Technology and Science

What Happened to NexOptic Technology Corp?

Last week, we witnessed a roller coaster ride in one of our largest holdings, NexOptic Technology (NXO). Here’s the scoop on what happened, as we explain the tactics of how big money firms short stocks. But don’t tell anyone, it’s supposed to be a secret……

3D Signatures’ TeloView™ Software Identifies and Stages Patients With Alzheimer’s Disease From a Cheek Swab

3D Signatures Inc. announces clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloView™ software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication i…

Flattening the Telescope — NexOptic to Unveil Blade Optics™ Prototype on April 4th

NexOptic Technology Corp. and Spectrum Optix Inc. are about to announce a major breakthrough at a media event to be held at the H.R. MacMillan Space Centre in Vancouver, British Columbia.The theme of the evening is “Flattening the Telescope,” and will mark the Companies’ first step in transforming what they believe may redefine many additional optical applications by utilizing th…

50/50: A Perfect Pilot Study from 3D Signatures on Blood-Based Prostate Cancer

3D Signatures Inc. just told the world that the results of a prospective blood-based prostate cancer pilot study using the Company’s proprietary TeloViewTM software platform was a perfect 50/50. Based on blinded blood samples, TeloViewTM correctly predicted the stability and aggressiveness of disease for each of the study’s 50 intermediate risk prostate cancer patients.…

New Study Shows 3D Signatures’ Telomere Analysis May Be an Effective Biomarker for Monitoring High Risk Prostate Cancer Patients

Data from a new study1 published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures Inc.’s technology platform, TeloView™, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined (hormonal) androgen deprivation therapy and radiation therapy.…